Skip to main content
. 2021 Jun 2;11:11583. doi: 10.1038/s41598-021-90765-8

Table 2.

Incidence of RVO in ESRD group, KT group and healthy controls.

Outcomes Groups RVO Duration Rate Model 1 Model 2 Model 3
Event Patient-years Per 1000 patient-years Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
RVO, total ESRD 290 51,047.6 5.68 5.54 (4.22, 7.23) < 0.001 5.71 (4.35, 7.50) < 0.001 3.21 (2.19, 4.70) < 0.001
KT 164 59,847.8 2.74 2.70 (2.02, 3.60) < 0.001 2.72 (2.03, 3.64) < 0.001 1.53 (1.02, 2.29) 0.034
Healthy 63 62,050.0 1.02 1 (ref) 1 (ref) 1 (ref)
Non-ischemic RVO ESRD 235 51,047.6 4.60 5.25 (3.90, 7.06) < 0.001 5.49 (4.02, 7.27) < 0.001 3.08 (2.03, 4.69) < 0.001
KT 135 59,847.8 2.26 2.59 (1.89, 3.56) < 0.001 2.61 (1.91, 3.58) < 0.001 1.49 (0.97, 2.30) 0.069
Healthy 54 62,050.0 0.87 1 (Ref.) 1 (Ref.) 1 (Ref.)
Ischemic RVO ESRD 55 51,047.6 1.07 7.27 (3.60, 14.72) < 0.001 7.53 (3.72, 15.24) < 0.001 3.89 (1.50, 10.06) 0.005
KT 29 59,847.8 0.48 3.33 (1.58, 7.04) 0.002 3.37 (1.59, 7.11) 0.002 1.75 (0.66, 4.66) 0.263
Healthy 9 62,050.0 0.15 1 (Ref.) 1 (Ref.) 1 (Ref.)

Analysis was performed using Cox regression. Model 1: not adjusted; Model 2: adjusted with age, sex; Model 3: adjusted with age, sex, diabetes mellitus, hypertension, dyslipidemia, Charlson comorbidity index, income status.

CI confidence interval, ESRD end stage renal disease, KT kidney transplantation, RVO renal vein occlusion.